MX2010002772A - Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus. - Google Patents

Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus.

Info

Publication number
MX2010002772A
MX2010002772A MX2010002772A MX2010002772A MX2010002772A MX 2010002772 A MX2010002772 A MX 2010002772A MX 2010002772 A MX2010002772 A MX 2010002772A MX 2010002772 A MX2010002772 A MX 2010002772A MX 2010002772 A MX2010002772 A MX 2010002772A
Authority
MX
Mexico
Prior art keywords
treatment
diabetes mellitus
pyridin
amino
glucokinase activators
Prior art date
Application number
MX2010002772A
Other languages
English (en)
Inventor
Jay Bradford Fell
John P Fischer
Eli M Wallace
Kevin Ronald Condroski
Thomas Daniel Aicher
Ronald Jay Hinklin
Mark Joseph Chicarelli
Steven Armen Boyd
Ajay Singh
Indrani W Gunawardana
Timothy M Turner
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2010002772A publication Critical patent/MX2010002772A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

S proporcionan compuestos de la fórmula (I): (ver fórmula (I)) en donde R2, R3, R13, L y D2 son como se define en la descripción, los cuales son útiles en el tratamiento y/o prevención de enfermedades o trastornos mediados por niveles deficientes de actividad glucocinasa o los cuales pueden ser tratados al activar glucocinasa, incluyendo, pero no limitados a, diabetes mellitus, tolerancia a glucosa alterada, IFG (glucosa en ayunas alterada) e IGF (glucemia en ayunas alterada), asi como otras enfermedades y trastornos tales como aquellos descritos en la presente.
MX2010002772A 2007-09-21 2008-09-15 Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus. MX2010002772A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97422507P 2007-09-21 2007-09-21
PCT/US2008/076401 WO2009042435A1 (en) 2007-09-21 2008-09-15 Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2010002772A true MX2010002772A (es) 2010-03-31

Family

ID=40250949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002772A MX2010002772A (es) 2007-09-21 2008-09-15 Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus.

Country Status (29)

Country Link
US (3) US8212045B2 (es)
EP (4) EP2573087A1 (es)
JP (1) JP5722037B2 (es)
KR (1) KR101566042B1 (es)
CN (1) CN101868459B (es)
AR (1) AR068628A1 (es)
AU (1) AU2008305294B2 (es)
BR (1) BRPI0816881A2 (es)
CA (1) CA2699718C (es)
CO (1) CO6270223A2 (es)
CR (2) CR11383A (es)
DK (1) DK2209778T3 (es)
EA (1) EA019104B1 (es)
ES (2) ES2569734T3 (es)
HK (2) HK1145498A1 (es)
HR (1) HRP20120814T1 (es)
IL (1) IL204264A (es)
MA (1) MA31779B1 (es)
MX (1) MX2010002772A (es)
MY (1) MY180558A (es)
NZ (1) NZ583538A (es)
PL (1) PL2209778T3 (es)
PT (1) PT2209778E (es)
SI (1) SI2209778T1 (es)
TN (1) TN2010000100A1 (es)
TW (1) TWI423799B (es)
UA (1) UA101166C2 (es)
WO (1) WO2009042435A1 (es)
ZA (2) ZA201002206B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044041B2 (en) * 2006-11-15 2011-10-25 Forest Laboratories Holdings Limited Phthalazine derivatives as inhibitors of protein kinase
AU2008305294B2 (en) 2007-09-21 2012-11-29 Array Biopharma Inc. Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011123572A1 (en) 2010-03-31 2011-10-06 The Scripps Research Institute Reprogramming cells
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CA2808590A1 (en) 2010-08-23 2012-03-01 Amgen Inc. Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes
BR112013023054A2 (pt) 2011-03-09 2019-09-24 Daiichi Sankyo Co Ltd composto, composição farmacêutica, ativador da glicocinase, uso de um composto, métodos para ativação da glicocinase, e para o tratamento e/ou prevenção de uma doença
CA2832286A1 (en) 2011-04-05 2012-10-11 Amgen Inc. Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013123444A1 (en) 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
US9296735B2 (en) 2012-05-18 2016-03-29 Amgen Inc. Method for the preparation of thiadiazoles
JP2015536993A (ja) * 2012-11-09 2015-12-24 アムジェン インコーポレイテッド （１ｓ）−１−［５−（｛３−［（２−メチルピリジン−３−イル）オキシ］−５−（ピリジン−２−イルスルファニル）ピリジン−２−イル｝アミノ）−１，２，４−チアジアゾール−３−イル］エタン−１，２−ジオールの結晶形態
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CA3080578A1 (en) 2017-10-30 2019-05-09 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
WO2019228363A1 (zh) * 2018-05-31 2019-12-05 华领医药技术（上海）有限公司 含有葡萄糖激酶激活剂和k-atp通道阻断剂的药物组合、组合物和复方制剂及其制备方法和用途

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983246A (en) 1974-04-04 1976-09-28 Fmc Corporation N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents
DE2949913A1 (de) * 1979-12-12 1981-06-25 Basf Ag, 6700 Ludwigshafen Azofarbstoffe
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0228168A (ja) * 1988-04-14 1990-01-30 Sankyo Co Ltd チアゾール誘導体
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
WO1993024442A1 (en) 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
CA2193725A1 (en) 1994-06-24 1996-01-04 David Cavalla Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity
GB9908410D0 (en) * 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1169038B9 (en) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
CN1242995C (zh) 1999-05-21 2006-02-22 比奥维特罗姆股份公司 化合物,它们的用途和制备方法
JP4144978B2 (ja) 1999-09-09 2008-09-03 富士フイルム株式会社 １，２，４−チアジアゾール誘導体の合成法
HUP0202682A3 (en) * 1999-09-10 2003-03-28 Merck & Co Inc Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
AU2735201A (en) 1999-12-28 2001-07-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
EA200300205A1 (ru) 2000-08-31 2003-06-26 Пфайзер Продактс Инк. Производные пиразола и их применение в качестве ингибиторов протеинкиназы
US20050209297A1 (en) * 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
AU2002213466A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
CA2425259A1 (en) 2000-10-11 2002-04-18 Tularik, Inc. Modulation of ccr4 function
CN1486302A (zh) 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
NZ526469A (en) 2000-12-21 2005-10-28 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US7144903B2 (en) * 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
EP1404672B1 (en) * 2001-06-22 2006-01-18 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
PT1479397E (pt) * 2002-02-05 2011-09-01 Astellas Pharma Inc Derivados de 2,4,6-triamino-1,3,5-triazina
ATE365733T1 (de) 2002-03-15 2007-07-15 Vertex Pharma Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60332433D1 (de) * 2002-03-15 2010-06-17 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
ATE433973T1 (de) * 2002-03-15 2009-07-15 Vertex Pharma Azolylaminoazine als inhibitoren von proteinkinasen
ATE468336T1 (de) * 2002-03-15 2010-06-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
MXPA04009541A (es) 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
WO2003091213A1 (fr) * 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amide ou sels de ces derives
AU2003249369A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
BR0313266A (pt) * 2002-08-09 2005-06-21 Astrazeneca Ab Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5
WO2004024159A1 (en) 2002-09-10 2004-03-25 Scios Inc. INHIBITORS OF TFGβ
NZ539013A (en) 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
WO2004041164A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
EP1603878B1 (en) * 2003-02-10 2013-01-02 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
EP1594512A4 (en) 2003-02-11 2007-07-11 Kemia Inc COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
MXPA05008619A (es) 2003-02-13 2005-11-04 Banyu Pharma Co Ltd Derivados novedosos de 2-piridincarboxamida.
ATE396731T1 (de) 2003-03-25 2008-06-15 Vertex Pharma Thiazole zur verwendung als inhibitoren von protein-kinasen
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
CN1845915A (zh) * 2003-09-02 2006-10-11 默克公司 作为亲代谢谷氨酸受体－5的调节剂的联吡啶胺和醚类化合物
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
EP1734040A4 (en) 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
RU2006138426A (ru) * 2004-04-02 2008-05-10 Новартис АГ (CH) Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой
RU2006139933A (ru) 2004-04-13 2008-05-20 Икаген, Инк. (Us) Полициклические пиридины как модуляторы калиевых ионных каналов
US7642354B2 (en) 2004-04-13 2010-01-05 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
JP2008526734A (ja) 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
JP2008527043A (ja) 2005-01-19 2008-07-24 ブリストル−マイヤーズ スクイブ カンパニー 血栓塞栓障害治療用のｐ２ｙ１受容体阻害剤としての２−フェノキシ−ｎ−（１，３，４−チアジアゾール−２−イル）ピリジン−３−アミン誘導体および関連化合物
DE102005025161A1 (de) 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg Derivate des Pyrimidins und Triazins und deren Verwendung
US7737151B2 (en) * 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
BRPI0615236A2 (pt) * 2005-08-31 2011-05-10 Astellas Pharma Inc derivado de tiazol
WO2007038387A2 (en) 2005-09-23 2007-04-05 Yale University Compounds and methods for the treatment of viruses and cancer
WO2007053345A1 (en) 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
BRPI0619708A2 (pt) 2005-11-03 2011-10-11 Vertex Pharma composto, composição, método para inibir a atividade da proteìna aurora quinase numa amostra biológica, método para tratar distúrbio proliferativo e método para tratar cáncer
KR20070052207A (ko) 2005-11-16 2007-05-21 주식회사 엘지생명과학 신규한 ｋｄｒ 억제제
ATE508126T1 (de) * 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
WO2007089512A1 (en) * 2006-01-27 2007-08-09 Array Biopharma Inc. Glucokinase activators
KR101440634B1 (ko) * 2006-03-24 2014-09-22 어레이 바이오파마 인크. 글루코키나제 활성제로서의 ２-아미노피리딘 유사체
EP2019822B1 (en) 2006-05-12 2010-09-08 AB Science A new process for the synthesis of 2-aminoxazole compounds
WO2008024963A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Benzene, pyridine, and pyridazine derivatives
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
DK2091918T3 (en) 2006-12-08 2014-12-01 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
US8362037B2 (en) 2007-03-23 2013-01-29 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
CA2682504C (en) 2007-04-05 2012-10-30 Amgen Inc. Aurora kinase modulators and method of use
US20090012091A1 (en) 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
WO2009022171A1 (en) 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
AU2008305294B2 (en) 2007-09-21 2012-11-29 Array Biopharma Inc. Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2009046784A1 (en) 2007-10-09 2009-04-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators

Also Published As

Publication number Publication date
US9079890B2 (en) 2015-07-14
WO2009042435A8 (en) 2009-10-08
KR101566042B1 (ko) 2015-11-04
AU2008305294B2 (en) 2012-11-29
TW200914007A (en) 2009-04-01
AR068628A1 (es) 2009-11-25
EP2727910A1 (en) 2014-05-07
SI2209778T1 (sl) 2012-12-31
DK2209778T3 (da) 2012-09-17
CA2699718C (en) 2014-05-27
ZA201002206B (en) 2011-06-29
PT2209778E (pt) 2012-12-06
KR20100080809A (ko) 2010-07-12
CN101868459A (zh) 2010-10-20
EP2209778B1 (en) 2012-08-29
IL204264A (en) 2015-06-30
EP2573087A1 (en) 2013-03-27
US8212045B2 (en) 2012-07-03
PL2209778T3 (pl) 2013-02-28
US20100204240A1 (en) 2010-08-12
US8853409B2 (en) 2014-10-07
MA31779B1 (fr) 2010-10-01
HK1145498A1 (en) 2011-04-21
EA201000515A1 (ru) 2010-10-29
UA101166C2 (ru) 2013-03-11
WO2009042435A1 (en) 2009-04-02
CO6270223A2 (es) 2011-04-20
CN101868459B (zh) 2013-12-18
JP5722037B2 (ja) 2015-05-20
EP2209778A1 (en) 2010-07-28
TWI423799B (zh) 2014-01-21
CR11383A (es) 2010-08-13
CR20150131A (es) 2015-04-30
ZA201102350B (en) 2012-09-26
JP2010540443A (ja) 2010-12-24
NZ583538A (en) 2012-06-29
BRPI0816881A2 (pt) 2015-03-17
ES2393824T3 (es) 2012-12-28
ES2569734T3 (es) 2016-05-12
US20150057448A1 (en) 2015-02-26
EP3078662A1 (en) 2016-10-12
CA2699718A1 (en) 2009-04-02
TN2010000100A1 (en) 2011-09-26
US20120277242A1 (en) 2012-11-01
MY180558A (en) 2020-12-02
HK1197821A1 (zh) 2015-02-18
AU2008305294A1 (en) 2009-04-02
EP2727910B1 (en) 2016-03-16
EA019104B1 (ru) 2014-01-30
HRP20120814T1 (hr) 2012-11-30

Similar Documents

Publication Publication Date Title
MX2010002772A (es) Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus.
ATE539748T1 (de) Glucokinaseaktivatoren
NO20064929L (no) Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2007041365A3 (en) 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
MY160123A (en) Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
PH12016501607A1 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
MX2010001560A (es) Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv.
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
UA100384C2 (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
TW200631580A (en) Substituted benzoquinolizine derivatives
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
ATE521608T1 (de) Glucokinaseaktivatoren
MX2007007174A (es) Derivados de cicloalquilamina.
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
MX2009009417A (es) Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
MX2010009922A (es) Activadores de piridazinona glucocinasa.
UY31352A1 (es) Activadores de glucocinasa
CY1116557T1 (el) Παραγωγα πυριδιν-2-υλ-αμινο-1,2,4-θειαδιαζολιου ως αναστολεις γλυκοκινασης για τη θεραπεια σακχαρωδους διαβητη

Legal Events

Date Code Title Description
FG Grant or registration